Evaluation of Target Organs Damage in Hypertensive Patients

Evaluation of Target Organs Damage in Hypertensive Patients Followed in General Practice With no Known Cardiovascular (CV) or Renal Disease, Stratified According to Blood Pressure Control

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01055353

Acronym

PreVENT-A GP

Enrollment

1857

Registered

2010-01-25

Start date

2010-01-31

Completion date

2010-06-30

Last updated

2011-05-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertensive, no Known Cardiovascular, no Known Renal Disease, Target Organs Damage

Keywords

Target organs damage, hypertensive patients

Brief summary

Evaluation of target organs damage in hypertensive patients with no known cardiovascular (CV) or renal disease, stratified according to level of blood pressure control

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* diagnosis of essential hypertension (treated or untreated); HT not discovered on the day of the consultation; no documented clinical cardiovascular or renal disease.

Exclusion criteria

Design outcomes

Primary

Measure	Time frame
To evaluate the frequency of evaluation of preclinical target organs damage in hypertensive patients with no known cardiovascular or renal disease, by taking blood pressure (controlled or uncontrolled HT*) into account	once / 1 Year

Secondary

Measure	Time frame
To describe the patient profile (socio-demographic, risk factors, comorbidities, global CV risk level estimated by the doctor and calculated retrospectively [according to ESH 2007]) associated with screening for target organs damage	—
To describe the modalities of patient follow-up and management	—
To compare the frequency of evaluation of target organs damage as a function of the modalities of management of CV risk factors at the time of the consultation.	—

Countries

France

Outcome results